局部晚期非小细胞肺癌显微肿瘤延伸的大小及预测因素
该回顾性研究纳入104例N2或N1期非小细胞肺癌术后患者,在数字化切片上测量显微镜下肿瘤延伸(MEmax)并分析预测因素。全队列中位MEmax为0.85 mm,腺癌95%的MEmax小于5.3 mm,鳞癌小于3.5 mm。多因素分析显示血管侵犯、组织学类型、肿瘤大小和高血压与MEmax相关,据此建议腺癌临床靶区 margins 可降至7 mm,鳞癌降至4 mm。
要点
- 全队列中位MEmax为0.85 mm,腺癌95%的MEmax小于5.3 mm,鳞癌小于3.5 mm。
- 血管侵犯、腺癌类型、较小肿瘤尺寸和高血压与更大的MEmax相关。
- 建议腺癌临床靶区 margin 可降至7 mm,鳞癌降至4 mm。
核心结论
- 考虑显微肿瘤延伸的临床靶区 margin 可降至腺癌7 mm、鳞癌4 mm。
研究设计与样本
- 回顾性研究,纳入70例N2期非小细胞肺癌术后放疗患者及34例N1或N2期鳞癌术后患者,共104例。
- 在数字化切片上肉眼勾画肿瘤边界,以最高40倍放大寻找边界外显微延伸并测量最大尺寸MEmax。
主要发现
- 全队列中位MEmax为0.85 mm(范围0-9.95 mm)。
- 95%腺癌的MEmax小于5.3 mm,无新辅助化疗亚组为6.5 mm。
- 95%鳞癌的MEmax小于3.5 mm,无新辅助化疗亚组为3.7 mm。
- 多因素分析显示血管侵犯(P = .0002)、组织学类型(腺癌大于鳞癌,P = .002)、肿瘤大小(与MEmax负相关,P = .024)和高血压(P = .03)与MEmax相关。
- 宏观组织学肿瘤大小与纵隔窗CT(相关系数0.845)及肺窗CT(相关系数0.836)的影像学肿瘤大小良好相关。
关键数值与推荐
- 腺癌临床靶区 margin 可降至7 mm,鳞癌可降至4 mm。
临床怎么用
- 根据组织学类型个体化设定临床靶区 margin,腺癌可考虑7 mm、鳞癌4 mm以减少正常组织照射。
- 血管侵犯、较小肿瘤尺寸和高血压患者可能需关注更大显微延伸。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy for locally advanced non-small cell lung cancer (NSCLC) should treat the whole tumor, including its microscopic extensions, and protect adjacent organs at risk as much as possible. The aim of our study is to evaluate the size of microscopic tumor extension (MEmax) in NSCLC, and search for potential predictive factors. METHODS AND MATERIALS: We retrospectively selected 70 patients treated with postoperative radiation therapy for a NSCLC with N2 nodal status, then 34 additional patients operated for a squamous cell lung cancer with N1 or N2 nodal status. On the digitized slides originating from the resected tumors of these 104 patients, we outlined the border of the tumor, as seen with the naked eye. We then searched for microscopic tumor extension outside of these borders with a magnification as high as 40 × and measured the maximum size of MEmax. RESULTS: The median MEmax in the whole cohort was 0.85 mm (0-9.95). The MEmax was <5.3 mm in 95% of adenocarcinomas (6.5 mm in the subgroup without neoadjuvant chemotherapy) and <3.5 mm in 95% of squamous cell carcinomas (3.7 mm in the subgroup without neoadjuvant chemotherapy). After multivariate analysis, the factors associated with the size of MEmax were vascular invasion (P = .0002), histologic type, with a wider MEmax for adenocarcinomas in comparison with squamous cell carcinomas (P = .002), tumor size, which was inversely related with the size of MEmax (P = .024), and high blood pressure (P = .03). Macroscopic histologic tumor size was well correlated with both radiologic tumor size on a mediastinal setting computed tomography (correlation coefficient of 0.845) and on a parenchymal setting computed tomography (correlation coefficient of 0.836). CONCLUSIONS: The clinical target volume margin, accounting for microscopic tumoral extension, could be reduced to 7 mm for adenocarcinomas and 4 mm for squamous cell carcinomas.
引用
- Meynard C, Mansuet-Lupo A, Giraud N, et al. Size and Predictive Factors of Microscopic Tumor Extension in Locally Advanced Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2021. PMID: 34126295. doi:10.1016/j.prro.2021.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。